Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Epigenetic Upregulation of the O-Linked Beta-N-Acetylglucosamine Transferase (OGT) in Response to Dronabinol Results in Antileukemic Efficacy In Vivo

Kerstin Maria Kampa-Schittenhelm, MD, Hans-Joerg Buehring, Michael Bonin, Wichard Vogel, MD, Lothar Kanz, Prof. Dr. MD, Thomas Haverkamp, Marcus M Schittenhelm, MD

Blood (2015) 126 (23): 2437.

https://doi.org/10.1182/blood.V126.23.2437.2437

Published: 2015

Journal Articles

An Fc-Engineered CD133 Antibody for Induction of NK Cell Reactivity Against Cancer Cells

Kathrin Rothfelder, Julia Leibold, Ludger Grosse-Hovest, PhD, Hans-Joerg Buehring, PhD, Gundram Jung, MD, Lothar Kanz, MD, Helmut R Salih, MD

Blood (2014) 124 (21): 2739.

https://doi.org/10.1182/blood.V124.21.2739.2739

Published: 2014

Journal Articles

Development and Preclinical Characterization of an Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity Against Myeloid Leukemia

Samuel Koerner, Julia Leibold, Ludger Grosse-Hovest, PhD, Hans-Joerg Buehring, PhD, Gundram Jung, MD, Lothar Kanz, MD, Helmut R. Salih, MD

Blood (2014) 124 (21): 2309.

https://doi.org/10.1182/blood.V124.21.2309.2309

Published: 2014

Journal Articles

Elimination Of Minimal Residual Disease (MRD) In AML Patients With a Novel Fc-Optimized FLT3 Antibody (4G8-SDIEM)

Helmut R. Salih, MD, Martin Hofmann, Ludger Grosse-Hovest, PhD, Tina Nuebling, PhD, Maximilian Bamberg, Steffen Aulwurm, PhD, Hans-Joerg Buehring, PHD, Wolfgang A. Bethge, MD, Lothar Kanz, MD, Gundram Jung, MD

Blood (2013) 122 (21): 1454.

https://doi.org/10.1182/blood.V122.21.1454.1454

Published: 2013

Journal Articles

Generation, Functional Characterization and Clinical Application of a Novel Fc-Optimized Anti-FLT3 Antibody for the Treatment of Acute Myeloid Leukemia

Helmut R. Salih, MD, Tina Baessler, Martin Hofmann, Ludger Grosse-Hovest, Maximilian Bamberg, Steffen Aulwurm, Hans-Joerg Buehring, Lothar Kanz, MD, Gundram Jung

Blood (2010) 116 (21): 2187.

https://doi.org/10.1182/blood.V116.21.2187.2187

Published: 2010

Journal Articles

Mesenchymal Stem Cell Differentiation Markers Shared with Soft Tissue Sarcomas

Stefan Wirths, Hans-Joerg Buehring, Lothar Kanz, Joerg T Hartmann, Hans-Georg Kopp

Blood (2008) 112 (11): 4755.

https://doi.org/10.1182/blood.V112.11.4755.4755

Published: 2008

NARROW

Epigenetic Upregulation of the O-Linked Beta-N-Acetylglucosamine Transferase (OGT) in Response to Dronabinol Results in Antileukemic Efficacy In Vivo

An Fc-Engineered CD133 Antibody for Induction of NK Cell Reactivity Against Cancer Cells

Development and Preclinical Characterization of an Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity Against Myeloid Leukemia

Elimination Of Minimal Residual Disease (MRD) In AML Patients With a Novel Fc-Optimized FLT3 Antibody (4G8-SDIEM)

Generation, Functional Characterization and Clinical Application of a Novel Fc-Optimized Anti-FLT3 Antibody for the Treatment of Acute Myeloid Leukemia

Mesenchymal Stem Cell Differentiation Markers Shared with Soft Tissue Sarcomas

Email alerts

ASH Publications

American Society of Hematology

Epigenetic Upregulation of the O-Linked Beta-N-Acetylglucosamine Transferase (OGT) in Response to Dronabinol Results in Antileukemic Efficacy In Vivo

An Fc-Engineered CD133 Antibody for Induction of NK Cell Reactivity Against Cancer Cells

Development and Preclinical Characterization of an Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity Against Myeloid Leukemia

Elimination Of Minimal Residual Disease (MRD) In AML Patients With a Novel Fc-Optimized FLT3 Antibody (4G8-SDIEM)

Generation, Functional Characterization and Clinical Application of a Novel Fc-Optimized Anti-FLT3 Antibody for the Treatment of Acute Myeloid Leukemia

Mesenchymal Stem Cell Differentiation Markers Shared with Soft Tissue Sarcomas

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only